Struma ovarii screening

Jump to navigation Jump to search

Struma ovarii Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Struma ovarii from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

ECG

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Struma ovarii screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Struma ovarii screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Struma ovarii screening

CDC on Struma ovarii screening

Struma ovarii screening in the news

Blogs on Struma ovarii screening

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Struma ovarii screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aravind Reddy Kothagadi M.B.B.S[2]

Overview

There is insufficient evidence to recommend routine screening for Struma ovarii. However, in cases of metastatic struma ovarii post total thyroidectomy along with radioiodine scanning and radioiodine ablation, the thyroglobulin levels must be monitored as a tumor marker, and diagnostic radioiodine scans should be done to screen for residual or recurrent disease.

Screening

  • There is insufficient evidence to recommend routine screening for Struma ovarii.
  • For follow-up as a marker of recurrence, serum thyroglobulin levels and I131 scan may be used. [1] [2] [3]
  • The I131 scan or thyroglobulin have no aid in the follow-up if thyroidectomy is not performed. [4]
  • In cases of metastatic struma ovarii post total thyroidectomy along with radioiodine scanning and radioiodine ablation, the thyroglobulin levels must be monitored as a tumor marker, and diagnostic radioiodine scans should be done to screen for residual or recurrent disease. [5]

References

  1. Volpi E, Ferrero A, Nasi PG, Sismondi P (2003). "Malignant struma ovarii: a case report of laparoscopic management". Gynecol. Oncol. 90 (1): 191–4. PMID 12821363.
  2. Zekri JM, Manifold IH, Wadsley JC (2006). "Metastatic struma ovarii: late presentation, unusual features and multiple radioactive iodine treatments". Clin Oncol (R Coll Radiol). 18 (10): 768–72. PMID 17168212.
  3. Sinha NK (2014). "Struma ovarii with elevated ca-125 levels and ascites mimicking advanced ca ovary". J Clin Diagn Res. 8 (3): 140–1. doi:10.7860/JCDR/2014/8005.4138. PMC 4003614. PMID 24783110.
  4. Balci TA, Kabasakal L (2005). "Is the I-131 whole-body scanning proper for follow-up management of the patients with malignant struma ovarii without performing the thyroidectomy?". Gynecol. Oncol. 99 (2): 520. doi:10.1016/j.ygyno.2005.04.017. PMID 15963556.
  5. McGill JF, Sturgeon C, Angelos P (2009). "Metastatic struma ovarii treated with total thyroidectomy and radioiodine ablation". Endocr Pract. 15 (2): 167–73. doi:10.4158/EP.15.2.167. PMID 19289330.

Template:WH Template:WS